

## ARECOR WINS INNOVATION IN BUSINESS AND BUSINESS PERSON OF THE YEAR AWARDS AT THE CAMBRIDGESHIRELIVE BUSINESS AWARDS

**Cambridge, UK,** 28 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Arecor has won the HCR Hewitsons Award for Innovation in Business, and CEO, Sarah Howell, has won Business Person of the Year at the UK CambridgeshireLive Business Awards.

The CambridgeshireLive Business Awards celebrate and recognise the region's best business talent, providing companies of all sizes, from pioneering start-ups to the powerhouses which drive the region's economy a chance to be recognised and be proud of their achievements.

Sarah Howell, Chief Executive Officer of Arecor, said: "We are delighted to have won the Award for Innovation in Business, and I am honoured to be recognised amongst such high-quality candidates leading innovative and dynamic companies in Cambridge. Innovation is at the heart of everything we do here at Arecor as we develop new advanced medicines from today's therapies to improve the lives of patients. These awards are an important external validation of Arecor's strengths and will support us to attract scientific talent to our growing business."

-ENDS-

## For more information, please contact:

Arecor Therapeutics plc <u>www.arecor.com</u>

Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com

Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060

Email: info@arecor.com

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: mo.noonan@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

**Consilium Strategic Communications** 

Chris Gardner, David Daley, Angela Gray Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com



## **Notes to Editors**

## **About Arecor**

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com